Financial Toxicity and Time Toxicity: Cost of Access to CAR-T and Bispecifics

Cost and access get dedicated oral slots at ASH 2026.

• Abstract 309 (Oral, 2:30–2:45 PM): “High rates of financial toxicity and time toxicity in patients initiating chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective study” (Thiruvengadam).
• Abstract 312 (Oral, 3:15–3:30 PM): “Expanding global access to an affordable CD19-directed CAR-T cell therapy, talicabtagene autoleucel: Real-world outcomes of patients across multiple continents” (Karulkar).
• Abstract 308 (Oral, 2:15–2:30 PM): Hub-and-spoke CAR-T care in Appalachia (DeCicco).
• Abstract 156 (Oral, 10:45–11:00 AM): Projected cost savings of an outpatient bispecific pathway (Singh).

The title language alone, “financial toxicity” and “time toxicity”, signals that burden on patients is being treated as a measurable outcome. Sponsors and sites planning cell therapy and bispecific studies may want to see how those measures are defined.